Annals of Internal Medicine has retracted a paper on treatments for Long COVID because the authors did not report dosing information for metformin, one of the drugs tested in the study. The editor-in-chief of the journal called the exclusion “sloppy” and “inaccurate.”
The same day the journal retracted the paper, it published a new version addressing the exclusion. But one researcher told Retraction Watch the replacement still leaves unanswered questions.
Published in March, the clinical trial found the antidepressant fluvoxamine – marketed as Luvox – reduced fatigue and metformin showed no significant benefit for patients with long-term fatigue and other chronic symptoms following COVID illness. Other studies have found fluvoxamine helped reduce depression in patients with Long COVID, and researchers have found starting metformin within three days of being diagnosed with COVID-19 can help prevent long-term effects of the disease.
Continue reading Journal retracts, republishes paper on Long COVID treatment trial








